This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory...
MDT continue to advance new technologies that are in development with increased investments in R&D. We expect these investments to create new markets, disrupt...
The Ambulatory Care segment delivered net operating revenues of $738mn in Q1FY22, which climbed 14.24% Y/Y. The improvement can be attributed to new service...
BAX is facing challenges related to increasing costs. The cost structure has been negatively impacted by rising rates of inflation as well as an...
ABT adopts the strategy of innovation to improve its product portfolio which can contribute towards the long term growth. In FY21, ABT continued to...
Encompass Health continue to invest in capacity expansions and opened 8 de novo IRFs and added 117 beds to existing hospitals, increasing licensed bed...
During Q1FY22, the company progressed their innovation pipeline, launching several new products. Examples include BD COR, where it launched molecular MX module, which fully...
Orthopaedics net sales increased 16.1% to $1.53bn in Q3FY21 as reported and 15.5% in constant currency, as foreign currency exchange rates positively impacted net...
BD COR™ System is a new, fully automated high-throughput molecular diagnostic platform that uses robotics and sample management software algorithms to set a new...
The revenue for BioPharma Solutions increased by 45% in Q3FY21. The strong performance driven by multiple collaborations to help manufacture COVID 19 vaccines on...
Boutique research firm providing Business, Investment and M&A research services focused on fast growing Technology, Healthcare, Life science and Industrial sectors.